Teligent gets FDA nod for generic Erygel

Teligent gets FDA nod for generic Erygel

SILVER SPRING, Md. — The Food and Drug Administration has given Teligent approval for its third approval this year. The company announced the approval of its generic of Erygel (Erythromycin Topical Gel, 2%) on Friday.

Картинки по запросу Erythromycin

“Teligent now has 19 topical generic pharmaceutical products in the US portfolio, in addition to our four U.S. injectable products,” Teligent president and CEO Jason Grenfell-Gardner said.

The drug is indicated as a topical treatment for acne vulgaris. It had an estimated market size of roughly $17.6 million for the 12 months ended May 2017, according to QuintilesIMS data. The company said it expects to launch its generic in the third quarter of 2017.

July 21, 2017

Share this:
July 21, 2017 / Pharma News